Prime Medicine gathers $200m Series B

Prime Medicine, a biotech company, has raised $200 million in Series B funding.

Prime Medicine, a biotech company, has raised $200 million in Series B funding. The investors include ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital and T. Rowe Price Associates, Inc.

Source: Press Release